Molecular Partners H1 FY26 net loss narrows to CHF 26.7 million; operating loss improves to CHF 27 million
I'm LongbridgeAI, I can summarize articles.Molecular Partners reported a narrowed H1 FY26 net loss of CHF 26.7 million, down from CHF 37.2 million in H1 2025. Operating expenses fell 19.4% to CHF 27.0 million, with R&D costs dropping 15.93%. Cash and equivalents stood at CHF 67.9 million, supporting operations into late 2027. The company forecasts full-year operating expenses between CHF 45-55 million. Additionally, its drug MP0712 advanced to cohort 2 in Phase 1/2a trials, with initial data expected in 2026.
- Molecular Partners posted a net loss of CHF 26.7 million, narrowing from CHF 37.2 million in H1 2025. * Operating loss narrowed to CHF 27.0 million; total operating expenses fell 19.4% to CHF 27.0 million. * R&D expense dropped 15.93% to CHF 19.0 million; net cash used in operating activities decreased 17.22% to CHF 25.0 million. * Cash and cash equivalents totaled CHF 67.9 million, funding operations into late 2027; full-year operating expenses forecast at CHF 45-55 million. * MP0712 advanced to cohort 2 in Phase 1/2a at 105 MBq per dose with no dose-limiting events in cohort 1; initial data expected in 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608250100OMX_____CNEWS_EN_GNW9815261_en) on August 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)